Peptide Library

Peptide Comparisons

Retatrutide vs. Tirzepatide: Two Receptors or Three

The headline numbers invite a direct comparison that the evidence does not support. One is approved with head-to-head data; the other is phase 2 with none.

Peptide Library Editorial · August 31, 2026 · 2 min read

Retatrutide vs. Tirzepatide: Two Receptors or Three — Peptide Library research guide

Tirzepatide activates two receptors: GIP and GLP-1. Retatrutide adds a third, the glucagon receptor. That is the whole structural difference, and everything else follows from it.

The comparison people actually want — which produces more weight loss — cannot be answered from the published evidence, because no trial has compared them.

One is approved, one is not. Tirzepatide is an approved medicine. Retatrutide is investigational, in phase 3, with no approval anywhere. This reports published trial data and is not dosing guidance.

Side by side

Retatrutide

Tirzepatide

Receptors

GIP + GLP-1 + glucagon

GIP + GLP-1

Status

Phase 3 ongoing

Approved

Best-reported trial figure

−24.2% at 48 weeks (phase 2)

−20.2% at 72 weeks (SURMOUNT-5)

Trial size for that figure

338 participants

751 participants

Head-to-head evidence

None

Versus semaglutide only

Why those two numbers cannot be compared

Placing −24.2% next to −20.2% invites an obvious conclusion. The comparison is not valid, for reasons that apply to cross-trial comparison generally:

  1. Different durations. 48 weeks versus 72 weeks. Weight trajectories do not stop at the endpoint.

  2. Different populations. Enrolment criteria, baseline characteristics, and settings differ between programmes.

  3. Different phases. Phase 2 results frequently attenuate in phase 3, where trials are larger and more heterogeneous.

  4. Different comparators. One was against placebo; SURMOUNT-5 was against an active drug.

SURMOUNT-5 is the illustration of why this matters. Before it, tirzepatide and semaglutide were compared across separate trials for years. A genuine head-to-head produced a cleaner answer than any amount of cross-trial arithmetic had. See the tirzepatide vs semaglutide comparison.

What the third receptor changes

GIP and GLP-1 both act largely on intake — appetite, gastric emptying, insulin response. Glucagon receptor agonism acts on expenditure.

That addition brings considerations tirzepatide does not have:

  • Heart rate. Increases have been observed with glucagon receptor agonism and are tracked in trial reporting.

  • Hepatic glucose output. Glucagon raises it, which cuts against what an incretin drug conventionally does.

  • Less accumulated safety data. Tirzepatide has post-approval exposure across large populations. Retatrutide has trial data only.

Survodutide takes the other route to the same idea — GLP-1 plus glucagon, without GIP.

Practical differences today

Retatrutide

Tirzepatide

Available as a medicine

No

Yes, on prescription

Quality assured

No — research material only

Yes, within the regulated channel

Dose guidance exists

Trial schedules only

Labelled escalation steps

Long-term safety data

Not yet

Accumulating post-approval

See the retatrutide dosage guide, its side effects, and the tirzepatide dosage chart.

Frequently asked questions

Is retatrutide stronger than tirzepatide?

Its phase 2 trial reported a larger figure. Without a head-to-head trial that is a comparison of two separate studies, not of two drugs.

When will retatrutide be approved?

Phase 3 programmes are ongoing. Outcomes and timelines are not something anyone can state with confidence in advance.

Which has better tolerability?

Both are dominated by dose-related gastrointestinal effects. Retatrutide adds glucagon-related considerations that tirzepatide does not have.

Research and educational use only. Peptide Library is an independent research and comparison platform and does not sell peptides. Nothing here is medical advice, dosing guidance, or a recommendation to administer any substance to a person or an animal. Consult a licensed clinician for anything concerning human health.

Sources

  1. 1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial — New England Journal of Medicine (2023) DOI: 10.1056/NEJMoa2301972 Source PubMed
  2. 2. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — New England Journal of Medicine (2025) Source PubMed

Author

Peptide Library Editorial

Editorial content from Peptide Library. Research and educational use only. Not medical advice.

Post on XLinkedIn

Research smarter with Peptide Library.

Compare peptides, review vendor data, and use research calculators in one place.

Explore the Library

Research and educational use only. Not medical advice. Peptide Library does not sell peptides.